In this episode of Conversations in Lung Cancer Research, A/Prof Mel Moore, along with thoracic oncologists Dr. Malinda Itchins and A/Prof Surein Arulananda, delve into the characteristics, detection, and treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. The podcast discusses recent advances, the efficacy of various treatments including small molecule tyrosine kinase inhibitors and monoclonal antibodies, and the potential future of targeted therapies. Special focus is given to the Phase 3 Papillon study and the drug Amivantamab, highlighting the need for next generation sequencing in clinical settings. Key challenges and questions in the field are also addressed, including the impact of co-mutations and optimal therapy sequencing.

This episode is sponsored by: Johnson & Johnson

(00:00) Introduction and Acknowledgements

(00:48) Introducing the Experts

(01:29) Understanding EGFR Exon 20 Insertion Mutations

(05:04) Challenges with Current Treatments

(06:30) Emerging Therapies and Clinical Trials

(11:03) Papillon Study Insights

(21:27) Future Directions and Unanswered Questions

(29:34) Conclusion and Final Thoughts